Nanoscale



CORRECTION

View Article Online
View Journal | View Issue



Cite this: Nanoscale, 2025, 17, 2365

Correction: Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery

Qianyuan He,^a Zhanjie Zhang,^a Haojie Liu,^b Zhan Tuo,^a Jie Zhou,^a Yan Hu,^a Yajie Sun,^a Chao Wan,^a Zushun Xu,^b Jonathan F. Lovell,^c Desheng Hu,*^d Kunyu Yang*^a and Honglin Jin*^a

DOI: 10.1039/d4nr90243b

rsc.li/nanoscale

Correction for 'Relieving immunosuppression during long-term anti-angiogenesis therapy using photo-dynamic therapy and oxygen delivery' by Qianyuan He et al., Nanoscale, 2020, **12**, 14788–14800, **https://doi.org/10.1039/D0NR02750B**.

The authors regret that an incorrect version of Fig. 4D was included in the originally published article. The correct version of Fig. 4 is shown below.


^aCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. E-mail: jin@hust.edu.cn, yangkunyu@medmail.com.cn

^bHubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Ministry of Education Key Laboratory for the Green Preparation and Application of Functional Materials, Hubei Key Laboratory of Polymer Materials, Hubei University, Wuhan, Hubei, 430062, China

^cDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, USA

^dDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. E-mail: desheng.hu@hust.edu.cn

Correction



12 14 16 10 Time (day)

Fig. 4 In vivo evaluation of SCM@BSA anti-tumor effects and distribution. (A) Therapeutic mechanism of SCM@BSA in the tumor site. (B) Body weight versus time after various treatments of the different groups (n = 5). (C) Relative tumor volume of the different groups after different treatments (n = 5). (D) Photographs of tumor-bearing mice at different times after different treatments. (E) Mn²⁺ biodistribution in the main organs 24 h after treatment. (F) Mn^{2+} biodistribution in the blood *versus* time. (G) Quantitative CD31 immunohistochemical assay of each group (n = 5). Data are presented as the mean \pm SEM (E, F: n = 3).

10 15 20 25

Time (h)

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.